Acrivon Therapeutics, Inc. Earnings Per Share (Basic)
Acrivon Therapeutics, Inc. (ACRV) reported Earnings Per Share (Basic) of -$0.43 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Acrivon Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.43.
- Acrivon Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.49.
- Acrivon Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.49.
- Acrivon Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.47.
- Acrivon Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.02.
- Acrivon Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$2.38.
- Acrivon Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.74.
- Acrivon Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$7.56.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.43 10-Q · filed 2026-08-12 | -$0.92 10-Q · filed 2026-08-12 | -$1.41 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2026-03-31 | -$0.49 10-Q · filed 2026-05-13 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.00 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$1.51 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.02 10-K · filed 2026-03-19 |
| 2025-09-30 | -$0.47 10-Q · filed 2025-11-13 | -$1.02 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.53 10-Q · filed 2025-11-13 | -$2.13 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-06-30 | -$0.55 10-Q · filed 2026-08-12 | -$1.06 10-Q · filed 2026-08-12 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.24 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-03-31 | -$0.51 10-Q · filed 2026-05-13 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.22 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2024-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$1.71 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$2.38 10-K · filed 2026-03-19 |
| 2024-09-30 | -$0.59 10-Q · filed 2025-11-13 | -$1.11 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.79 10-Q · filed 2025-11-13 | -$2.58 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-06-30 | -$0.52 10-Q · filed 2025-08-13 | -$1.20 10-Q · filed 2025-08-13 | -$2.02 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$2.68 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-03-31 | -$0.73 10-Q · filed 2025-05-14 | -$1.59 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$2.25 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$2.88 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2023-12-31 | -$0.86 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$1.52 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$2.15 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$2.74 10-K · filed 2025-03-27 |
| 2023-09-30 | -$0.66 10-Q · filed 2024-11-13 | -$1.29 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.87 10-Q · filed 2024-11-13 | -$2.60 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$0.63 10-Q · filed 2024-08-13 | -$1.22 10-Q · filed 2024-08-13 | -$1.94 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$3.15 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-03-31 | -$0.58 10-Q · filed 2024-05-14 | -$1.31 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$2.66 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$4.01 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2022-12-31 | -$0.80 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$2.80 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$4.88 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$7.56 10-K · filed 2024-03-28 |
| 2022-09-30 | -$5.17 10-Q · filed 2023-11-09 | -$8.47 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$12.55 10-Q · filed 2023-11-09 | -$15.00 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$3.29 10-Q · filed 2023-08-11 | -$7.37 10-Q · filed 2023-08-11 | -$9.82 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$11.20 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-03-31 | -$4.08 10-Q · filed 2023-05-09 | -$6.53 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$7.91 derived: net income ÷ weighted average shares · filed 2023-11-09 | |
| 2021-12-31 | -$2.45 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$3.83 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$9.32 10-K · filed 2023-03-28 | |
| 2021-09-30 | -$1.38 10-Q · filed 2022-12-15 | -$6.86 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |